GuidelineArthritis care & research2022
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease.
Guideline in Arthritis care & research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 59 citations in OpenAlex.
- Long-Term Coronary Outcomes and Follow-Up After Kawasaki Disease: Insights from a 25-Year Follow-Up Cohort.Journal of clinical medicine · 2026Article
- Comparison of Systemic Corticosteroid Therapy Practices Between Pediatric and Adult Rheumatologists: A Multicenter Survey Study.Rheumatology and therapy · 2026Article
- Multimodal Echocardiographic Assessment in Intravenous Immunoglobulin-Resistant Kawasaki Disease: From Prediction to Long-Term Surveillance.Echocardiography (Mount Kisco, N.Y.) · 2026Review
- Monocyte Single-Cell-Type Gene Expression Analysis Differentiates Kawasaki Disease From Viral Infection With High Specificity.Journal of cellular and molecular medicine · 2026Article
- The Autophagy-Inflammasome Axis as a Molecular Switch: From Persistent Inflammation to Vascular Remodeling in IVIG-Resistant Kawasaki Disease.International journal of molecular sciences · 2026Review
- Diagnostic approaches to Kawasaki disease worldwide: the results from the JIR-CliPS network.Rheumatology (Oxford, England) · 2026Article
- Construction and validation of a diagnostic model for Kawasaki disease based on neutrophil-related genes and analysis of immune infiltration.Translational pediatrics · 2026Article
- Kawasaki disease vs. MIS-C in a child with congenital coronary artery anomaly: a case report.Frontiers in pediatrics · 2026Article
- Clinical outcomes of giant coronary aneurysms in South Asian children with Kawasaki disease.Pediatric rheumatology online journal · 2025Article
- Clinical Practice Variation Among Pediatric Rheumatologists Treating Kawasaki Disease: Results of a North American Survey.Children (Basel, Switzerland) · 2025Article
- Community engagement in health guidelines and other normative products: a methodological review.Bulletin of the World Health Organization · 2025Review
- Interpretable web-based machine learning model for predicting intravenous immunoglobulin resistance in Kawasaki disease.Italian journal of pediatrics · 2025Article
- Establishment and validation of a predictive model for coronary artery lesions in children with KDSS.Italian journal of pediatrics · 2025Article
- Pharmacoeconomic Analysis and Considerations for the Management of Kawasaki Disease in the Arab Countries-A Multinational, Multi-Institutional Project of the Kawasaki Disease Arab Initiative (Kawarabi) (A Project Methodology Paper).Turkish archives of pediatrics · 2025Article
- The protective role of steroids on coronary arteries in the acute phase of Kawasaki disease for high risk patients: a retrospective study.Frontiers in pediatrics · 2025Article
- Single-cell transcriptomic analysis reveals a systemic immune dysregulation in intravenous immunoglobulin non-responsive Kawasaki disease.Frontiers in immunology · 2025Article
- A bibliometric analysis from 2004 to 2024 reveals research hotspots and trends in the immunotherapy for vasculitis.Human vaccines & immunotherapeutics · 2024Article
- Severity of Acute Kawasaki Disease Can Be Predicted by Evaluating the Body Temperature at the Completion of an Initial Immunoglobulin Treatment.Journal of clinical medicine · 2024Article
- [Characteristics of intestinal microbiota in the acute phase of Kawasaki disease in infants and children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Article
- Mitochondrial DNA release via the mitochondrial permeability transition pore activates the cGAS-STING pathway, exacerbating inflammation in acute Kawasaki disease.Cell communication and signaling : CCS · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 20 institutions in 2 countries.
Funding
Abstract
objectiveTo provide evidence-based recommendations and expert guidance for the management of Kawasaki disease (KD), focusing on clinical scenarios more commonly addressed by rheumatologists.
methodsSixteen clinical questions regarding diagnostic testing, treatment, and management of KD were developed in the Patient/Population, Intervention, Comparison, and Outcomes (PICO) question format. Systematic literature reviews were conducted for each PICO question. We used the Grading of Recommendations, Assessment, Development and Evaluation method to assess the quality of evidence and formulate recommendations. Each recommendation required consensus from at least 70% of the Voting Panel.
resultsWe present 1 good practice statement, 11 recommendations, and 1 ungraded position statement to guide the management of KD and clinical scenarios of suspected KD. These recommendations for KD are focused on situations in which input from rheumatologists may be requested by other managing specialists, such as in cases of treatment-refractory, severe, or complicated KD. The good practice statement affirms that all patients with KD should receive initial treatment with intravenous immunoglobulin (IVIG). In addition, we developed 7 strong and 4 conditional recommendations for the management of KD or suspected KD. Strong recommendations include prompt treatment of incomplete KD, treatment with aspirin, and obtaining an echocardiogram in the setting of unexplained macrophage activation syndrome or shock. Conditional recommendations include use of IVIG with other adjuvant agents for patients with KD and high-risk features of IVIG resistance and/or coronary artery aneurysms. These recommendations endorse minimizing risk to the patient by using established therapy promptly at disease onset and identifying situations in which adjunctive therapy may be warranted.
conclusionThese recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and use of echocardiography in patients with suspected or confirmed KD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.